<DOC>
	<DOCNO>NCT00904020</DOCNO>
	<brief_summary>Patients diagnosis postherpetic neuralgia ( PHN ) , diabetic neuropathy ( DN ) , low back pain ( LBP ) currently receive analgesic regimen contain gabapentin participate Phase IV clinical trial ass effectiveness Lidoderm® administer daily ( q24h ) 14 day treatment PHN , DN , LBP patient partial response regimen contain gabapentin .</brief_summary>
	<brief_title>A Study Effectiveness And Safety Of Lidoderm® As Add-On Treatment Patients With Postherpetic Neuralgia , Diabetic Neuropathy , Low Back Pain</brief_title>
	<detailed_description />
	<mesh_term>Back Pain</mesh_term>
	<mesh_term>Low Back Pain</mesh_term>
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Diabetic Neuropathies</mesh_term>
	<mesh_term>Neuralgia , Postherpetic</mesh_term>
	<mesh_term>Lidocaine</mesh_term>
	<criteria>Were currently receive analgesic regimen contain gabapentin Had stable dose gabapentin least 14 day ( dose ±10 % 14 day ) Had partial response gabapentincontaining analgesic regimen define average daily pain intensity score &gt; 4 ) 10 scale , 0 pain 10 pain ba patient ever imagine ( Question 5 Brief Pain Inventory [ BPI ] within 24 hour prior screen visit For diabetic patient , hemoglobin A1c level &lt; 0.13 ( normal range , 0.0470.064 ) Had neurological condition associate pain diagnosis , opinion investigator , would interfere ability participate study Had receive epidural steroid/local anesthetic injection within 14 day prior study entry Had receive trigger point injection within 14 day prior study entry Had receive Botox injection within 3 month prior study entry Were take lidocainecontaining product could discontinue receive Lidoderm Were take Class 1 antiarrhythmic drug ( e.g. , mexiletine , tocainide )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
</DOC>